HSD17B2 and benign neoplasm: The expression of HSD17B2 in breast cancer is important in its capacity to oxidize E2 into E1 and protect the tissue from its activity, and HSD17B2 expression was shown to be reduced in breast cancer compared with benign tumors [56, 62].